Novel MRI Assessment of Prostate Cancer VALIDATE-PRO (VALIDATE-PRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05017181

Recruitment Status : Recruiting

First Posted : August 23, 2021

Last Update Posted : August 23, 2021

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

University College, London

Study Description

Brief Summary:

For 50 years the diagnosis of prostate cancer has been with Prostate Specific Antigen (PSA) blood testing and prostate biopsy. However, this approach resulted in over-diagnosis, over-treatment and missed clinical important cancers. Multi-parametric MRI (mp-MRI) has provided a solution to some of these issues and the National Institute for health and Care Excellence has advocated the use of mp-MRI before biopsy in men with a suspicion for prostate cancer.

However, important challenges remain and the current way we pick up and assess prostate cancer can be improved. mp-MRI can miss significant cancer in around 11% of cases, 30% of positive MRI scans turn out not to have significant cancer at biopsy. Lastly, 34% of mp-MRI lesions are scored as in-determinant which sometimes makes decisions for further investigation and treatment unclear.

There are also difficulties predicting patients who will have progression of their disease or those who will not suffer harm from their cancer. Therefore the development of non-invasive tests and markers that can tell apart aggressive and non-aggressive disease would be extremely useful in deciding what treatment approach suits individual patients.

This study will investigate the use of three different novel MRI methods; Vascular, extracellular and restricted diffusion for cytometry in tumours (VERDICT), Luminal Imaging (LI) and hyperpolarised [1-13C]-pyruvate MRI (HYP-MRI). These scans help us to look at the microstructure as well as the metabolism of prostate tissue and may offer ways to better differentiate aggressive vs non-aggressive disease.

These scans will be performed in men with prostate cancer suitable for active surveillance at baseline and 1 year later to assess for prognostic indicators for progression in early prostate cancer.HYP-MRI will also be performed in men undergoing radical prostatectomy for validation of image findings and pathology. Whilst some men will have repeat scanning to asses for the repeatability of these techniques.

Condition or disease
Prostate Cancer

Show detailed description

Detailed Description:

PURPOSE AND DESIGN

The purpose of this study is to assess the ability of novel MRI techniques and their derived metrics in the diagnosis and prognostication of prostate cancer. Improving the diagnostic accuracy and investigating biomarkers with non- invasive MRI techniques have the promise of reducing unnecessary biopsies or radical treatment, as well as detecting those likely to progress at an earlier stage.

Vascular, Extracellular and Restricted Cytometry in Tumours (VERDICT) MRI

Diffusion-weighted imaging (DWI) is one of the most important sequences in mp-MRI of the prostate which reflects the diffusivity of water in cells and differs in cancerous tumour due to changes in cellular density, size, shape and arrangement. VERDICT is a novel framework which uses a more complex 3-compartment tissue model for diffusion of water; 1. Water trapped in cells, 2. Water in the vascular network and 3. Interstitial water. This allows us to make estimates of specific tissue properties such as the size and packing density of the cells, the vascular extracellular- extravascular space (EES) volume fractions. This methods is more biologically specific compared to conventional DWI. Studies in tumour xenograft models of colorectal cancer showed its ability to detect such known differences in the microstructure. At UCL we have applied VERDICT to the prostates of 78 men and were able to successfully differentiate between benign or clinically insignificant cancer and clinically significant tumours. This technique can be applied on commercially available MRI scanners and requires no additional contrast agents or requirements for the patient compared to conventional mp-MRI of the prostate.

Luminal Index (LI) MRI

Using a multi-echo T2 sequence we can differentiate between the relatively long T2 values of the luminal space and the short T2 values of the stromal and epithelial cells to estimate the fractional volume of water in each MR voxel, the luminal water fraction (LWF). Studies have shown a good correlation between LWF and histologically measure luminal fractional volume and hence promise to detect prostate cancer and predict Gleason score. Our refined local LI MRI sequence has been very good at differentiating clinically significant and non-significant tumours. This technique also requires no additional contrast agents or patient requirements to be completed.

Hyperpolarised [1-13C]-pyruvate MRI (HYP-MRI)

Cancer cell rely on enhanced glycolysis for their energy supply, a phenomenon known as the Warburg effect. This is a key discriminator of malignancy and normal tissues and has been successfully targeted with well-established imaging techniques such as Fluorodeoxyglucose (FDG) - Positron Emission Tomography (PET). HYP-MRI is able to image a part of this metabolic process in real-time. An injectable solution containing 13C labelled pyruvate which is hyperpolarised onsite in order to increase the eventual detectable signal. The naturally occurring metabolise pyruvate is converted to lactate with the attached 13C tag persisting enabling us to track the presence and conversion of pyruvate to lactate after the injection. It heralds the potential to differentiate tumours which are more likely to grow and metastasise from those which won't. This sequence requires an additional injection compared to standard mp-MRI and also uses an endorectal coil which is place inside the rectum for the duration of the scan.

The main objectives of this study are as follow and are addressed in three sub-studies:

To biologically validate HYP-MRI with correlation against biological measurements in men undergoing radical prostatectomy (BioVal: 44 patients)
Clinical validation of novel MRI techniques (VERDICT/LI/HYP-MRI) derived measurements for differentiating patients with aggressive (progressive) and indolent (non-progressive) prostate cancer in men entering active surveillance (ProVal: 120 patients)
Technical validation of novel MRI techniques (VERDICT/LI/HYP-MRI) through assessment of repeatability metrics from derived parameters (TecVal: 20 patients)

Study Design

Layout table for study information

Study Type :	Observational [Patient Registry]
Estimated Enrollment :	234 participants
Observational Model:	Case-Only
Time Perspective:	Prospective
Target Follow-Up Duration:	1 Year
Official Title:	Assessment of Diagnostic and Prognostic VALue, Identification of bIological Correlates, and Determination of TEchnical Performance of Novel Metabolic and Microstructural MRI in PROstate Cancer
Actual Study Start Date :	January 29, 2021
Estimated Primary Completion Date :	December 1, 2023
Estimated Study Completion Date :	June 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Prostate cancer

MedlinePlus related topics: Prostate Cancer

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
BioVal BioVal is a single site validation study to determine the histological correlates underpinning signals derived from 13C-pyruvate HYP-MRI in men with known prostate cancer scheduled for prostatectomy.
ProVal ProVal is a single site, prospective, longitudinal observational cohort study to determine the prognostic value of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known early prostate cancer on active surveillance.
TecVal TecVal is a multi-site validation study to determine the inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.

Outcome Measures

Primary Outcome Measures :

ProVal Primary Objective [ Time Frame: 3 years ]
To determine the prognostic value of VERDICT metrics for risk classification of patients with early prostate cancer suitable for active surveillance.

Quantitive value: fIC (intracellular (IC) volume fraction) among others within model.
ProVal Primary Objective [ Time Frame: 3 years ]
To determine the prognostic value of Luminal Index for risk classification of patients with early prostate cancer suitable for active surveillance.

Quantitive value: Luminal index
ProVal Primary Objective [ Time Frame: 3 years ]
To determine the prognostic value of 13C-HYP-MRI for risk classification of patients with early prostate cancer suitable for active surveillance.

Quantitive value: Lactate and pyruvate ratio parameters.
BioVal Primary Objective [ Time Frame: 3 years ]
To estimate the association of 13C-HYP-MRI derived quantitative metrics against histological features of prostate cancer.

Quantitive value: Lactate and pyruvate ratio parameters.
BioVal Primary Objective [ Time Frame: 3 years ]
To estimate the association of 13C-HYP-MRI derived quantitative metrics against histological features of prostate cancer.

Quantitive value: Gleason Grade
TecVal Primary Objective [ Time Frame: 3 years ]
Inter-site repeatability and intra-site reproducibility of signals derived from VERDICT, Luminal Index MRI and 13C-pyruvate HYP-MRI in men with known prostate cancer.

Metric: Repeatability and reproducibility co-efficients

Secondary Outcome Measures :

ProVal Secondary Objective [ Time Frame: 3 year ]
To examine the effects of histological progression of prostate cancer on VERDICT and LI-MRI quantitative metrics To determine whether baseline imaging metrics can predict time to radiological progression.

Metric: Gleason grade (used in combination with previous metrics discussed)

Other Outcome Measures:

ProVal Tertiary Objective [ Time Frame: 3 years ]
To link quantitative mpMRI, VERDICT MRI, LI-MRI and 13C-HYP-MRI quantitative features with molecular, genetic, epigenetic, transcriptomic and proteomic immune measurements made within patients recruited to the linked RECONCILE study.

Metric: genetic, molecular and epigenetic measurements.

Biospecimen Retention: Samples With DNA

Prostatectomy digital histopathology metrics and biochemical stains for the prostatectomy arm of the study.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

BioVal Cohort: Men scheduled for Prostatectomy

ProVal Cohort: Men initiating active surveillance and treatment for low grade disease.

Criteria

Inclusion Criteria:

Men aged >18 years
Pre-biopsy mp-MRI study performed within preceding 4 months
Likert/PIRADS score 4-5/5 lesion and/or biopsy confirmed Prostate cancer
Willing and able to provide written informed consent

Exclusion Criteria:

Men who suffer with claustrophobia or are unable to have an MRI e.g. implantable defibrillator, brain aneurysm clips or other implant, severe obesity or unable to lay still for length of scan.
Men with an impaired renal function (eGFR <30)
Previous prostate radiotherapy/focal treatment
Hormonal treatment for prostate cancer within preceding 3 months from consenting to the study.
Dementia or other neurological condition meaning participant lacks the capacity to consent.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05017181

Contacts

Layout table for location contacts

Contact: Adam Retter, MD	7398762767 ext +044	rhmaret@ucl.ac.uk
Contact: Nicola Murhead, PhD		n.muirhead@ucl.ac.ukk

Locations

Layout table for location information

United Kingdom
University College London	Recruiting
London, United Kingdom
Contact: Adam Retter, MD 7398762767 ext +044 rmharet@ucl.ac.uk

Sponsors and Collaborators

University College, London

Investigators

Layout table for investigator information

Principal Investigator:	Shonit Punwani, MD PhD	UCL

More Information

Layout table for additonal information

Responsible Party:	University College, London
ClinicalTrials.gov Identifier:	NCT05017181
Other Study ID Numbers:	129237
First Posted:	August 23, 2021 Key Record Dates
Last Update Posted:	August 23, 2021
Last Verified:	August 2021

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by University College, London:


MRI biomarker novel technique cancer validation

Additional relevant MeSH terms:

Layout table for MeSH terms

Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms	Neoplasms by Site Neoplasms Prostatic Diseases

To Top